Premium
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients
Author(s) -
Vigna E.,
De Vivo A.,
Gentile M.,
Morelli R.,
Lucia E.,
Mazzone C.,
Recchia A.G.,
Vianelli N.,
Morabito F.
Publication year - 2010
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2010.00519.x
Subject(s) - visceral leishmaniasis , medicine , amphotericin b , leishmaniasis , leishmania , zoonosis , virology , antifungal , immunology , dermatology , parasite hosting , world wide web , computer science
E. Vigna, A. De Vivo, M. Gentile, R. Morelli, E. Lucia, C. Mazzone, A.G. Recchia, N. Vianelli, F. Morabito. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Transpl Infect Dis 2010: 12: 428–431. All rights reserved. Abstract: Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First‐line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L‐AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus‐negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L‐AMB.